Informational only — Not medical advice. Always consult a licensed healthcare provider.

Shasthya স্বাস্থ্য · Health, made simple
বাং
Community data Updated 22 hours ago
🌐 বাংলায় দেখুন

Indications

Cancer

Talazoparib is a poly (ADP-ribose) polymerase (PARP) inhibitor, and it is indicated in two conditions. The first is BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Here it is used as a single agent in adult patients who have a deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. The second is HRR gene-mutated mCRPC. In this case talazoparib is given in combination with Enzalutamide to adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Talazoparib blocks poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1 and PARP2, which help the cell repair its DNA. Laboratory studies used cancer cell lines with defects in DNA repair genes, including BRCA1 and BRCA2. In these studies, the cell-killing effect of Talazoparib may involve two things: inhibition of PARP enzymatic activity, and a greater build-up of PARP-DNA complexes. Together these lead to DNA damage, slower cell proliferation and apoptosis. Talazoparib also showed anti-tumor activity in patient-derived xenograft breast cancer models that carried mutated BRCA1, mutated BRCA2, or wild type BRCA1 and BRCA2.

Pregnancy & Breastfeeding

Pregnancy: Animal studies and the way Talazoparib works in the body suggest it can harm an unborn baby when given to a pregnant woman. There are no data on the use of Talazoparib in pregnant women, so the actual risk from the medicine is not known. Pregnant women, and women who could become pregnant, should be told about the possible risk to the baby.

Lactation: No data exist on whether Talazoparib passes into human breast milk. Nothing is known either about its effect on milk production or on a breastfed child.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: For gBRCAm HER2-negative locally advanced or metastatic breast cancer, patients should be selected for Talazoparib treatment based on the presence of germline BRCA mutations. In HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC), selection is based on the presence of HRR gene mutations (ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C). The recommended dosage of Talazoparib in gBRCAm HER2-negative locally advanced or metastatic breast cancer is 1 mg taken orally once daily until disease progression or unacceptable toxicity. If adverse reactions occur, interrupting the dose or reducing it should be considered. The recommended dosage in HRR gene-mutated mCRPC is 0.5 mg taken orally once daily in combination with Enzalutamide, also until disease progression or unacceptable toxicity. Talazoparib can be taken with or without food. The capsules should be swallowed whole, and they should not be opened or dissolved. If a patient vomits or misses a dose, they should be told to take the next prescribed dose at the usual time.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.